vs
渤健（BIIB）与NVR, Inc.（NVR）财务数据对比。点击上方公司名可切换其他公司
NVR, Inc.的季度营收约是渤健的1.2倍（$2.7B vs $2.3B），NVR, Inc.净利率更高（13.4% vs -2.1%，领先15.6%），NVR, Inc.同比增速更快（-4.7% vs -7.1%），渤健自由现金流更多（$468.0M vs $436.0M），过去两年NVR, Inc.的营收复合增速更高（7.8% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
NVR, Inc.是总部位于美国弗吉尼亚州雷斯顿的知名住宅建造企业，同时运营抵押贷款银行及产权服务相关业务。公司业务主要布局美国东海岸，覆盖14个州及华盛顿特区，2021年有22%的营收来自华盛顿大都会区。
BIIB vs NVR — 直观对比
营收规模更大
NVR
是对方的1.2倍
$2.3B
营收增速更快
NVR
高出2.5%
-7.1%
净利率更高
NVR
高出15.6%
-2.1%
自由现金流更多
BIIB
多$32.0M
$436.0M
两年增速更快
NVR
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $2.7B |
| 净利润 | $-48.9M | $363.8M |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | — |
| 净利率 | -2.1% | 13.4% |
| 营收同比 | -7.1% | -4.7% |
| 净利润同比 | -118.3% | -20.5% |
| 每股收益（稀释后） | $-0.35 | $120.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBNVR
| Q4 25 | $2.3B | $2.7B | ||
| Q3 25 | $2.5B | $2.6B | ||
| Q2 25 | $2.6B | $2.6B | ||
| Q1 25 | $2.4B | $2.4B | ||
| Q4 24 | $2.5B | $2.8B | ||
| Q3 24 | $2.5B | $2.7B | ||
| Q2 24 | $2.5B | $2.6B | ||
| Q1 24 | $2.3B | $2.3B |
净利润BIIBNVR
| Q4 25 | $-48.9M | $363.8M | ||
| Q3 25 | $466.5M | $342.7M | ||
| Q2 25 | $634.8M | $333.7M | ||
| Q1 25 | $240.5M | $299.6M | ||
| Q4 24 | $266.7M | $457.4M | ||
| Q3 24 | $388.5M | $429.3M | ||
| Q2 24 | $583.6M | $400.9M | ||
| Q1 24 | $393.4M | $394.3M |
毛利率BIIBNVR
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBNVR
| Q4 25 | -2.5% | — | ||
| Q3 25 | 22.0% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 28.3% | — | ||
| Q1 24 | 20.3% | — |
净利率BIIBNVR
| Q4 25 | -2.1% | 13.4% | ||
| Q3 25 | 18.4% | 13.1% | ||
| Q2 25 | 24.0% | 12.8% | ||
| Q1 25 | 9.9% | 12.5% | ||
| Q4 24 | 10.9% | 16.1% | ||
| Q3 24 | 15.8% | 15.7% | ||
| Q2 24 | 23.7% | 15.3% | ||
| Q1 24 | 17.2% | 16.9% |
每股收益（稀释后）BIIBNVR
| Q4 25 | $-0.35 | $120.85 | ||
| Q3 25 | $3.17 | $112.33 | ||
| Q2 25 | $4.33 | $108.54 | ||
| Q1 25 | $1.64 | $94.83 | ||
| Q4 24 | $1.82 | $139.09 | ||
| Q3 24 | $2.66 | $130.50 | ||
| Q2 24 | $4.00 | $120.69 | ||
| Q1 24 | $2.70 | $116.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $18.3B | $3.9B |
| 总资产 | $29.4B | $5.9B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
总债务BIIBNVR
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
股东权益BIIBNVR
| Q4 25 | $18.3B | $3.9B | ||
| Q3 25 | $18.2B | $4.0B | ||
| Q2 25 | $17.6B | $3.8B | ||
| Q1 25 | $17.0B | $4.0B | ||
| Q4 24 | $16.7B | $4.2B | ||
| Q3 24 | $16.4B | $4.3B | ||
| Q2 24 | $15.9B | $4.1B | ||
| Q1 24 | $15.2B | $4.3B |
总资产BIIBNVR
| Q4 25 | $29.4B | $5.9B | ||
| Q3 25 | $29.2B | $6.0B | ||
| Q2 25 | $28.3B | $5.9B | ||
| Q1 25 | $28.0B | $6.2B | ||
| Q4 24 | $28.0B | $6.4B | ||
| Q3 24 | $28.3B | $6.5B | ||
| Q2 24 | $26.8B | $6.4B | ||
| Q1 24 | $26.6B | $6.5B |
负债/权益比BIIBNVR
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $439.7M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $436.0M |
| 自由现金流率自由现金流/营收 | 20.5% | 16.1% |
| 资本支出强度资本支出/营收 | 1.9% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 1.21× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $1.1B |
8季度趋势，按日历期对齐
经营现金流BIIBNVR
| Q4 25 | $511.9M | $439.7M | ||
| Q3 25 | $1.3B | $438.7M | ||
| Q2 25 | $160.9M | $35.1M | ||
| Q1 25 | $259.3M | $207.8M | ||
| Q4 24 | $760.9M | $637.0M | ||
| Q3 24 | $935.6M | $358.3M | ||
| Q2 24 | $625.8M | $232.7M | ||
| Q1 24 | $553.2M | $146.5M |
自由现金流BIIBNVR
| Q4 25 | $468.0M | $436.0M | ||
| Q3 25 | $1.2B | $433.3M | ||
| Q2 25 | $134.3M | $26.8M | ||
| Q1 25 | $222.2M | $200.7M | ||
| Q4 24 | $721.6M | $631.5M | ||
| Q3 24 | $900.6M | $350.1M | ||
| Q2 24 | $592.3M | $226.3M | ||
| Q1 24 | $507.3M | $137.5M |
自由现金流率BIIBNVR
| Q4 25 | 20.5% | 16.1% | ||
| Q3 25 | 48.4% | 16.6% | ||
| Q2 25 | 5.1% | 1.0% | ||
| Q1 25 | 9.1% | 8.4% | ||
| Q4 24 | 29.4% | 22.2% | ||
| Q3 24 | 36.5% | 12.8% | ||
| Q2 24 | 24.0% | 8.7% | ||
| Q1 24 | 22.1% | 5.9% |
资本支出强度BIIBNVR
| Q4 25 | 1.9% | 0.1% | ||
| Q3 25 | 1.8% | 0.2% | ||
| Q2 25 | 1.0% | 0.3% | ||
| Q1 25 | 1.5% | 0.3% | ||
| Q4 24 | 1.6% | 0.2% | ||
| Q3 24 | 1.4% | 0.3% | ||
| Q2 24 | 1.4% | 0.2% | ||
| Q1 24 | 2.0% | 0.4% |
现金转化率BIIBNVR
| Q4 25 | — | 1.21× | ||
| Q3 25 | 2.73× | 1.28× | ||
| Q2 25 | 0.25× | 0.11× | ||
| Q1 25 | 1.08× | 0.69× | ||
| Q4 24 | 2.85× | 1.39× | ||
| Q3 24 | 2.41× | 0.83× | ||
| Q2 24 | 1.07× | 0.58× | ||
| Q1 24 | 1.41× | 0.37× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
NVR
| Home Building Segment | $2.6B | 97% |
| Mortgage Banking Segment | $77.4M | 3% |
